The purpose of this study is to test whether an investigational infusion of islet cells (called VX-880) would be safe, tolerable and effective in providing better control of blood sugar levels for Type 1 Diabetes by improving insulin independence and islet cell function. This will be tested in patients with episodes of severe hypoglycemia and difficulty recognizing low blood sugar.
The purpose of this study is to assess the overall efficacy, safety and tolerability of BIVV020 for prevention and treatment of antibody-mediated rejection in adult kidney transplant recipients.
The purpose of this study is to evaluate the immune response and safety of a new vaccine in preventing diseases due to infection with respiratory syncytial virus (RSV). This RSV vaccine will be tested in older adults who are recipients of lung or kidney transplants and are at an increased risk of RSV compared to healthy older adults.
The purpose of the study is to investigate the safety and efficacy of itolizumab versus placebo in individuals with acute graft-versus-host disease, when combined with corticosteroids as a first line treatment.
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant (ReGIFT)
The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors >45 years after brain death (DBD).
Canadian-Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK)
Patients on the waiting list for kidney transplantation are at risk for coronary artery disease (CAD). The optimal strategy to monitor and maintain the cardiac fitness of these patients is unknown. Currently patients without any symptoms of CAD undergo annual testing to determine if they have disease. This study will determine if screening is necessary.
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation have not been achieved. The specific drug combination that provides the best outcomes with the least amount of side effects is not known. Each kidney transplant center uses the combination of drugs that they believe is optimal.
Closed for Recruitment
The purpose of this study is to evaluate the efficacy, safety and tolerability of axatilimab at three different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least two prior lines of systemic therapy.